SCHEMBL95173

SCHEMBL95173

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CSC[C@H](N)C(=O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DOT1L Q8TEK3 6/20 0.82
EHMT2 Q96KQ7 4/20 0.82
NNMT P40261 4/20 0.82
CARM1 Q86X55 3/20 0.82
NSD2 O96028 3/20 0.82
SETD7 Q8WTS6 3/20 0.82
PNMT P11086 2/20 0.82
DNMT1 P26358 2/20 0.82
DNMT3B Q9UBC3 2/20 0.82
TRDMT1 O14717 2/20 0.82
PRMT5 O14744 2/20 0.82
INMT O95050 2/20 0.82
METTL3 Q86U44 2/20 0.82
PRMT1 Q99873 2/20 0.82
EHMT1 Q9H9B1 2/20 0.82
METTL14 Q9HCE5 2/20 0.82
SUV39H1 O43463 1/20 0.82
PRMT3 O60678 1/20 0.82
HNMT P50135 1/20 0.82
WDR5 P61964 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27092958 1.00 DOT1L (0.82) DOT1LEHMT2NNMTCARM1NSD2
SCHEMBL27092961 1.00 DOT1L (0.82) DOT1LEHMT2NNMTCARM1NSD2
SCHEMBL19433776 1.00 DOT1L (0.82) DOT1LEHMT2NNMTCARM1NSD2
SCHEMBL19433014 1.00 DOT1L (0.82) DOT1LEHMT2NNMTCARM1NSD2
SCHEMBL19433069 1.00 DOT1L (0.82) DOT1LEHMT2NNMTCARM1NSD2
SCHEMBL18661551 1.00 DOT1L (0.82) DOT1LEHMT2NNMTCARM1NSD2
S-Adenosylhomocysteine SCHEMBL13033864 0.90 DOT1L (1.00) DOT1LEHMT2NNMTCARM1NSD2
S-Adenosylhomocysteine SCHEMBL18826562 0.90 DOT1L (1.00) DOT1LEHMT2NNMTCARM1NSD2
S-Adenosylhomocysteine SCHEMBL14434697 0.90 DOT1L (1.00) DOT1LEHMT2NNMTCARM1NSD2
S-Adenosylhomocysteine SCHEMBL21160481 0.90 DOT1L (1.00) DOT1LEHMT2NNMTCARM1NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115754299-B Homocysteine acid detection kit 南京岚煜生物科技有限公司 2025-04-08 CN claimed
EP-4223883-A1 PROCESS FOR PRODUCING TRYPTAMINES Infinit Biosystems (DE) 2023-08-09 EP claimed
CN-107209173-B Method for determining a patient's unique nutritional needs 雀巢产品有限公司 2020-02-07 CN claimed
EP-2055695-B1 COMPOSITION FOR THE ALKYLATION AND A METHOD FOR DETOXIFYING A HARMFUL COMPOUND BY USING THE COMPOSITION NIPPON SHEET GLASS CO LTD (JP) 2016-12-14 EP claimed
US-8847000-B2 Composition for alkylation and method for detoxifying a harmful compound by using the composition NIPPON SHEET GLASS COMPANY, LIMITED (JP) 2014-09-30 US claimed
US-8728800-B2 Assay method AXIS SHIELD ASA (NO) 2014-05-20 US claimed
US-8618345-B2 Method of detoxifying a methyl compound NIPPON SHEET GLASS COMPANY, LIMITED (JP) 2013-12-31 US claimed
US-8133912-B2 Methyl aquocobyrinic acid derivative, alkylation composition, and method for detoxifying a harmful compound by utilizing the composition NIPPON SHEET GLASS COMPANY, LIMITED (JP) 2012-03-13 US claimed
US-20100286424-A1 METHOD OF DETOXIFYING A HARMFUL COMPOUND NIPPON SHEET GLASS COMPANY, LIMITED (JP) 2010-11-11 US claimed
US-20100228073-A1 METHOD OF DETOXIFYING A METHYL COMPOUND NIPPON SHEET GLASS COMPANY, LIMITED (JP) 2010-09-09 US claimed
EP-2100643-A1 METHOD OF MAKING METHYL COMPOUND HARMLESS Nippon Sheet Glass Company Limited (JP) 2009-09-16 EP claimed
EP-2055695-A1 COMPOSITION FOR ALKYLATION, AND METHOD FOR DETOXIFICATION OF TOXIC COMPOUND USING THE COMPOSITION Nippon Sheet Glass Company Limited (JP) 2009-05-06 EP claimed
EP-2048148-A1 METHYL AQUOCOBYRINIC ACID DERIVATIVE, ALKYLATION COMPOSITION, AND METHOD FOR DETOXIFYING HARMFUL COMPOUND BY UTILIZING THE COMPOSITION Nippon Sheet Glass Company Limited (JP) 2009-04-15 EP claimed
US-7323319-B2 RNA containing coenzymes, biotin, or fluorophores, and methods for their preparation and use THE UNIVERSITY OF SOUTHERN MISSISSIPPI (US) 2008-01-29 US claimed
EP-1834645-A1 Autoinducer synthase modulating compounds and uses therefor UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2007-09-19 EP claimed
US-20040241649-A1 RNA CONTAINING COENZYMES, BIOTIN, OR FLUOROPHORES, AND METHODS FOR THEIR PREPARATION AND USE UNIVERSITY OF SOUTHERN MISSISSIPPI (US) 2004-12-02 US claimed
US-20040152660-A1 Autoinducer synthase modulating compounds and uses therefore THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2004-08-05 US claimed
US-20030054512-A1 AUTOINDUCER SYNTHASE MODULATING COMPOUNDS AND USES THEREFORE LAHIVE AND COCKFIELD 2003-03-20 US claimed
EP-1100513-A1 AUTOINDUCER SYNTHASE MODULATING COMPOUNDS AND USES THEREFOR UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2001-05-23 EP claimed
WO-2000006177-A1 AUTOINDUCER SYNTHASE MODULATING COMPOUNDS AND USES THEREFOR THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2000-02-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286424-A1 METHOD OF DETOXIFYING A HARMFUL COMPOUND SCLY, AS3MT, GSTA2 DOT1L 732/4885EHMT2 473/4885NNMT 545/4885
US-20040152660-A1 Autoinducer synthase modulating compounds and uses therefore COASY, FDPS, BLVRB DOT1L 4738/4885EHMT2 3654/4885NNMT 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.